These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34655841)

  • 1. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
    Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
    Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
    Zhang B; Liu Z; Xia S; Liu Q; Gou S
    Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
    Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
    Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
    Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
    Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
    Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
    Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
    Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
    Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
    Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
    Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
    Wang Z; Liu L; Dai H; Si X; Zhang L; Li E; Yang Z; Chao G; Zheng J; Ke Y; Lihong S; Zhang Q; Liu H
    Bioorg Med Chem; 2021 Aug; 43():116265. PubMed ID: 34192644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
    Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
    Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFR
    Dai L; Qin F; Xie Y; Zhang B; Zhang Z; Liang S; Chen F; Huang X; Wang H
    Bioorg Chem; 2023 Jun; 135():106510. PubMed ID: 37018899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
    Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W
    Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
    Das D; Xie L; Wang J; Shi J; Hong J
    Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and SAR study of 2-aminopyrimidines with diverse Michael addition acceptors for chemically tuning the potency against EGFR
    Shao J; Liu S; Liu X; Pan Y; Chen W
    Bioorg Med Chem; 2020 Oct; 28(19):115680. PubMed ID: 32912431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.
    Li DD; Lv PC; Zhang H; Zhang HJ; Hou YP; Liu K; Ye YH; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(16):5012-22. PubMed ID: 21763148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.